WHO Grade 2 Glioma

This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial enlisting 45 patients (31 with glioblastoma) into the high-grade glioma cohort (oth… (full text at CIViC)

PMID 34838156 · Wen et al., 2022 · Open in CIViC

In this case series, two patients with BRAF V600E mutant pleomorphic xanthoastrocytoma were treated using the BRAF inhibitor dabrafenib and trametinib in combination with the MEK inhibitor trametinib.… (full text at CIViC)

PMID 28984141 · Brown et al., 2017 · Open in CIViC

An anaplastic pleomorphic xanthoastrocytoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with radiation and temozolomid… (full text at CIViC)

PMID 25092772 · Lee et al., 2016 · Open in CIViC

In a series of 54 supratentorial ependymomas with ZFTA::RELA fusions (termed fusions between C11orf95 and RELA at time of publication), homozygous deletion of CDKN2A was found in 9 cases and hemizygou… (full text at CIViC)

PMID 32514758 · Jünger et al., 2020 · Open in CIViC

From a phase one clinical trial, pediatric patients with refractory CNS malignancies were administered 300-1150 mg/m2 twice daily of ERBB2 and EGFR inhibitor lapatinib. The maximum-tolerated dose was … (full text at CIViC)

PMID 20713864 · Fouladi et al., 2010 · Open in CIViC

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

FUBP1 truncating mutations occur somatically with high specificity for adult oligodendroglioma and are considered oncogenic in that setting

PMID 21817013 · Bettegowda et al., 2011 · Open in CIViC

Taylor, et al. (2014) presented 26 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age 6 years, median overall survival was 11 months, 20 of… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

Buczkowicz, et al. (2014) analyzed 74 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age at diagnosis 6 years, median survival of 10 months… (full text at CIViC)

PMID 24705254 · Buczkowicz et al., 2014 · Open in CIViC

Yoshimoto, et al. (2017) analyzed 411 gliomas of Japanese patients (median age of 46 years (ranged between 1 to 87 years)). Direct sequencing revealed H3F3A p.K27R in one 51 years of age oligodendrogl… (full text at CIViC)

PMID 28447171 · Yoshimoto et al., 2017 · Open in CIViC

Taylor, et al. (2014) presented 26 diffuse midline glioma, H3 K27M-mutant (here referred to as diffuse intrinsic pontine glioma) cases (median age 6 years, median overall survival was 11 months, 20 of… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

Mariet et al. identified a somatic H3C4 (HIST1H3D) p.Lys28Met (K27M) mutation in a posterior fossa group A ependymoma (EPN_PFA) from an 8-year-old male. The tumor showed H3 K27M immunoreactivity, loss… (full text at CIViC)

PMID 36104744 · Mariet et al., 2022 · Open in CIViC

In a cohort of 1,010 WHO grade II-III diffuse gliomas assessed by direct sequencing, IDH1 R132H was identified in 103/128 (80.5%) oligodendrogliomas and 111/174 (63.8%) anaplastic oligodendrogliomas. … (full text at CIViC)

PMID 19554337 · Hartmann et al., 2009 · Open in CIViC

In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations. A phase I clinical trial of the AG-120 IDH1 inhibit… (full text at CIViC)

PMID 23558169 · Rohle et al., 2013 · Open in CIViC

An international multi-institutional study identified108 patients with a methylation profile of supratentorial ependymoma, ZFTA fusion-positive, by whole genome DNA methylation profiling. The study fo… (full text at CIViC)

PMID 37287693 · Ng et al., 2023 · Open in CIViC

In a series of 54 cases of ependymoma diagnosed in children </= 3 years, methylation profiling of all tumours was undertaken as part of a prospective clinical trial (SJYC07 - maximal safe surgical res… (full text at CIViC)

PMID 30976811 · Upadhyaya et al., 2019 · Open in CIViC

In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival.

PMID 19901104 · van den Bent et al., 2009 · Open in CIViC

In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation o… (full text at CIViC)

PMID 16541434 · Levin et al., 2006 · Open in CIViC

In an analysis of 13 cases of supratentorial tumors with ZFTA rearrangements without RELA involvement, all were found to have DNA methylation profiles similar to ZFTA::RELA supratentorial ependymoma. … (full text at CIViC)

PMID 34389065 · Tauziède-Espariat et al., 2021 · Open in CIViC

Histological, molecular, and clinical analysis of 26 histologically prototypical isomorphic diffuse gliomas with a specific DNA methylation profile distinct from other glial/glio-neuronal brain tumors… (full text at CIViC)

PMID 31563982 · Wefers et al., 2020 · Open in CIViC

Copy-number analysis was performed on 44 diffuse pediatric low-grade gliomas (PLGGs) to identify recurrent alterations. The most significant event, focal 8q13.1 gain, was observed in 28% (5/18) of dif… (full text at CIViC)

PMID 23633565 · Ramkissoon et al., 2013 · Open in CIViC

Comprehensive molecular studies (through whole genome, whole exome, transcriptome sequencing, genome-wide copy number analysis, clustering analysis by DNA methylation profiling, mutation hotspot analy… (full text at CIViC)

PMID 26810070 · Qaddoumi et al., 2016 · Open in CIViC

The study compiled the clinicopathologic and molecular features of 46 gliomas with a MYB or MYBL1 alteration diagnosed at a single center. The tumors showed low-grade histopathologic features and were… (full text at CIViC)

PMID 31595312 · Chiang et al., 2019 · Open in CIViC

A 14.6-year-old male [ID: 6] with a family history of neurofibromatosis type 1 (NF1) affecting both parents and a sibling. The patient was asymptomatic at diagnosis, and a biopsy of the left frontal g… (full text at CIViC)

PMID 35945463 · Lucas et al., 2022 · Open in CIViC

Single strand conformation polymorphism and sequencing was used on human tumors to determine tumor NF2 genotype. This is a nonsense mutation.

PMID 10433955 · Ebert et al., 1999 · Open in CIViC

Blood or tumor specimens of 37 unrelated adult patients with ependymomas related to neurofibromatosis Type 2 (NF2) underwent sequencing of the NF2 gene to reveal germline variants. Overall, 64% were f… (full text at CIViC)

PMID 21294614 · Plotkin et al., 2011 · Open in CIViC

SEC61G::EGFR (5'UTR::e14) (5'-UTR of SEC61G and 3'-UTR of EGFR) was detected in ependymoma as a change sensitive to gefitinib (also confirmed by mice xenografts model). Screening of 16 ependymoma pati… (full text at CIViC)

PMID 29092923 · Servidei et al., 2017 · Open in CIViC

In the evaluation of 275 oligodendroglial tumors, the specific genotype at amino acid 72 of TP53 (Arg/Arg, Arg/Pro, or Pro/Pro) was not associated grade of malignancy (low- vs. high-grade, P = 0.650) … (full text at CIViC)

PMID 17854663 · Idbaih et al., 2007 · Open in CIViC

A total of 15 pediatric patients with supratentorial ependymomas harboring YAP1::MAMLD1 fusions were reported. In all 15 cases, YAP1::MAMLD1 fusions were confirmed by RT-PCR and sequencing. In the ma… (full text at CIViC)

PMID 30246434 · Andreiuolo et al., 2019 · Open in CIViC

This is a case report of a 26-year-old male patient who sufferred 3 grand mal seizures and was found to have a left frontal lobe ependymoma with a YAP1::FAM118B fusion. No other genetic alterations we… (full text at CIViC)

PMID 33480048 · Wang et al., 2021 · Open in CIViC

DNA methylation profiling of 500 ependymal tumors identified 9 molecular profiles with 3 occurring in the supratentorial compartment (designated ST EPN). RNA sequencing performed in 7 of the 13 cases… (full text at CIViC)

PMID 25965575 · Pajtler et al., 2015 · Open in CIViC

In an analysis of 13 cases of supratentorial tumors with ZFTA rearrangements without RELA involvement, all were found to have DNA methylation profiles similar to ZFTA::RELA supratentorial ependymoma. … (full text at CIViC)

PMID 34389065 · Tauziède-Espariat et al., 2021 · Open in CIViC

In an analysis of 13 cases of supratentorial glial tumors with ZFTA rearrangements without RELA involvement, all were found to have DNA methylation profiles similar to ZFTA::RELA supratentorial ependy… (full text at CIViC)

PMID 34389065 · Tauziède-Espariat et al., 2021 · Open in CIViC

In an analysis of 13 cases of supratentorial glial tumors with ZFTA rearrangements without RELA involvement, all were found to have DNA methylation profiles similar to ZFTA::RELA supratentorial ependy… (full text at CIViC)

PMID 34389065 · Tauziède-Espariat et al., 2021 · Open in CIViC

Ependymoma RELA fusion-positive is a genetically defined ependymoma subtype accepted as a distinct entity in the 2016 WHO classification of CNS tumors. This variant accounts for the majority of suprat… (full text at CIViC)

PMID 27157931 · Louis et al., 2016 · Open in CIViC

Pajtler et al. generated genome-wide DNA methylation profiles for 500 ependymal tumors using the Illumina 450k methylation array. Tumors were classified into nine molecular subgroups of which 88 supra… (full text at CIViC)

PMID 25965575 · Pajtler et al., 2015 · Open in CIViC